Treatments in Respiratory Medicine

, Volume 4, Issue 5, pp 309–316 | Cite as

Biomarkers Predicting Response to Corticosteroid Therapy in Asthma

  • Christopher E. Brightling
  • Ruth H. Green
  • Ian D. Pavord
Leading Article


International guidelines on the management of asthma support the early introduction of corticosteroids to control symptoms and to improve lung function by reducing airway inflammation. However, not all individuals respond to corticosteroids to the same extent and it would be an advantage to be able to predict the response to corticosteroid treatment. Several biomarkers have been assessed following treatment with corticosteroids including measures of lung function, peripheral blood and sputum indices of inflammation, exhaled gases and breath condensates. The most widely examined measures in predicting a response to corticosteroids are airway hyperresponsiveness, exhaled nitric oxide (eNO) and induced sputum. Of these, sputum eosinophilia has been demonstrated to be the best predictor of a short-term response to corticosteroids. More importantly, directing treatment at normalizing the sputum eosinophil count can substantially reduce severe exacerbations. The widespread utilization of sputum induction is hampered because the procedure is relatively labor intensive. The measurement of eNO is simpler, but incorporating the assessment of NO in an asthma management strategy has not led to a reduction in exacerbation rates. The challenge now is to either simplify the measurement of a sputum eosinophilia or to identify another inflammatory marker with a similar efficacy as the sputum eosinophil count in predicting both the short- and long-term responses to corticosteroids.


Asthma Airway Inflammation Airway Smooth Muscle Asthma Control Eosinophil Count 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were provided to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Wardlaw AJ, Brightling C, Green R, et al. Eosinophils in asthma and other allergic diseases. Br Med Bull 2000; 56(4): 985–1003PubMedCrossRefGoogle Scholar
  2. 2.
    Brightling CE, Bradding P, Symon FA, et al. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346(22): 1699–705PubMedCrossRefGoogle Scholar
  3. 3.
    Kay AB. Pathology of mild, severe, and fatal asthma. Am J Respir Crit Care Med 1996; 154 (2 Pt 2): S66–9PubMedGoogle Scholar
  4. 4.
    National Heart, Lung and Blood Institute. Global intiative for asthma: global strategy for asthma management and prevention. Bethesda, MD; 1995Google Scholar
  5. 5.
    British Thoracic Society. Scottish Intercollegiate Guidelines Network (SIGN). British guidelines on the management of asthma. Thorax 2003; 58 Suppl. 1: i1–94CrossRefGoogle Scholar
  6. 6.
    Juniper EF, Kline PA, Vanzieleghem MA, et al. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J 1990; 3(10): 1122–7PubMedGoogle Scholar
  7. 7.
    Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990; 142(4): 832–6PubMedGoogle Scholar
  8. 8.
    Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325(6): 388–92PubMedCrossRefGoogle Scholar
  9. 9.
    Adams NP, Bestall JB, Jones PW. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2000; (4): CD002738Google Scholar
  10. 10.
    Loren ML, Chai H, Leung P, et al. Corticosteroids in the treatment of acute exacerbations of asthma. Ann Allergy 1980; 45(2): 67–71PubMedGoogle Scholar
  11. 11.
    Beasley R. The burden of asthma with specific reference to the United States. J. Allergy Clin Immunol 2002; 109 (5 Suppl.): S482–9PubMedCrossRefGoogle Scholar
  12. 12.
    Crimi E, Spanevello A, Neri M, et al. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. Am J Respir Crit Care Med 1998; 157(1): 4–9PubMedGoogle Scholar
  13. 13.
    Rosi E, Scano G. Association of sputum parameters with clinical and functional measurements in asthma. Thorax 2000; 55(3): 235–8PubMedCrossRefGoogle Scholar
  14. 14.
    Ronchi MC, Piragino C, Rosi E, et al. Do sputum eosinophils and ECP relate to the severity of asthma? Eur Respir J 1997; 10(8): 1809–13PubMedCrossRefGoogle Scholar
  15. 15.
    Veen JC, Smits HH, Ravensberg AJ, et al. Impaired perception of dyspnea in patients with severe asthma: relation to sputum eosinophils. Am J Respir Crit Care Med 1998; 158(4): 1134–41PubMedGoogle Scholar
  16. 16.
    Roisman GL, Peiffer C, Lacronique JG, et al. Perception of bronchial obstruction in asthmatic patients: relationship with bronchial eosinophilic inflammation and epithelial damage and effect of corticosteroid treatment. J Clin Invest 1995; 96(1): 12–21PubMedCrossRefGoogle Scholar
  17. 17.
    Salome CM, Reddel HK, Ware SI, et al. Effect of budesonide on the perception of induced airway narrowing in subjects with asthma. Am J Respir Crit Care Med 2002; 165(1): 15–21PubMedGoogle Scholar
  18. 18.
    Parameswaran K, Pizzichini E, Pizzichini MM, et al. Clinical judgement of airway inflammation versus sputum cell counts in patients with asthma. Eur Respir J 2000; 15(3): 486–90PubMedCrossRefGoogle Scholar
  19. 19.
    Reddel HK, Jenkins CR, Marks GB, et al. Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 2000; 16(2): 226–35PubMedCrossRefGoogle Scholar
  20. 20.
    Gershman NH, Wong HH, Liu JT, et al. Low- and high-dose fluticasone propionate in asthma; effects during and after treatment. Eur Respir J 2000; 15(1): 11–8PubMedCrossRefGoogle Scholar
  21. 21.
    Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240(4854): 889–95PubMedCrossRefGoogle Scholar
  22. 22.
    Carson-Jurica MA, Schrader WT, O’Malley BW. Steroid receptor family: structure and functions. Endocr Rev 1990; 11(2): 201–20PubMedCrossRefGoogle Scholar
  23. 23.
    Gronemeyer H. Control of transcription activation by steroid hormone receptors. FASEB J 1992; 6(8): 2524–9PubMedGoogle Scholar
  24. 24.
    Jonat C, Rahmsdorf HJ, Park KK, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 1990; 62(6): 1189–204PubMedCrossRefGoogle Scholar
  25. 25.
    Auphan N, Didonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270(5234): 286–90PubMedCrossRefGoogle Scholar
  26. 26.
    Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145(3): 669–74PubMedGoogle Scholar
  27. 27.
    Ward C, Pais M, Bish R, et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002; 57(4): 309–16PubMedCrossRefGoogle Scholar
  28. 28.
    Hoshino M, Nakamura Y, Sim JJ, et al. Inhaled corticosteroid reduced lamina reticularis of the basement membrane by modulation of insulin-like growth factor (IGF)-I expression in bronchial asthma. Clin Exp Allergy 1998; 28(5): 568–77PubMedCrossRefGoogle Scholar
  29. 29.
    Hoshino M, Takahashi M, Takai Y, et al. Inhaled corticosteroids decrease vascularity of the bronchial mucosa in patients with asthma. Clin Exp Allergy 2001; 31(5): 722–30PubMedCrossRefGoogle Scholar
  30. 30.
    Bentley AM, Hamid Q, Robinson DS, et al. Prednisolone treatment in asthma: reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med 1996; 153(2): 551–6PubMedGoogle Scholar
  31. 31.
    Orsida BE, Li X, Hickey B, et al. Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax 1999; 54(4): 289–95PubMedCrossRefGoogle Scholar
  32. 32.
    Knox AJ. The scientific rationale of combining inhaled glucocorticoids and long acting Beta 2 adrenoceptor agonists. Curr Pharm Des 2002; 8(20): 1863–9PubMedCrossRefGoogle Scholar
  33. 33.
    Bjornson BH, Harvey JM, Rose L. Differential effect of hydrocortisone on eosinophil and neutrophil proliferation. J Clin Invest 1985; 76(3): 924–9PubMedCrossRefGoogle Scholar
  34. 34.
    Meagher LC, Cousin JM, Seckl JR, et al. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996; 156(11): 4422–8PubMedGoogle Scholar
  35. 35.
    Meijer RJ, Postma DS, Kauffman HF, et al. Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin Exp Allergy 2002; 32(7): 1096–103PubMedCrossRefGoogle Scholar
  36. 36.
    Pavord ID, Brightling CE, Woltmann G, et al. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353(9171): 2213–4PubMedCrossRefGoogle Scholar
  37. 37.
    Mondino C, Ciabattoni G, Koch P, et al. Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. J Allergy Clin Immunol 2004; 114(4): 761–7PubMedCrossRefGoogle Scholar
  38. 38.
    Hunter CJ, Brightling CE, Woltmann G, et al. A comparison of the validity of different diagnostic tests in adults with asthma. Chest 2002; 121(4): 1051–7PubMedCrossRefGoogle Scholar
  39. 39.
    Verscheiden P, Cartier A, L’Archeveque J, et al. Compliance with and accuracy of daily self-assessment of peak expiratory flows (PEF) in asthmatic subjects over a three month period. Eur Respir J 1996; 9(5): 880–5CrossRefGoogle Scholar
  40. 40.
    Diner B, Brenner B, Camargo CA, et al. Inaccuracy of “personal best” peak expiratory flow rate reported by inner-city patients with acute asthma. J Asthma 2001; 38(2): 127–32PubMedCrossRefGoogle Scholar
  41. 41.
    Reddel HK, Toelle BG, Marks GB, et al. Analysis of adherence to peak flow monitoring when recording of data is electronic. BMJ 2002; 324(7330): 146–7PubMedCrossRefGoogle Scholar
  42. 42.
    Reddel H, Ware S, Marks G, et al. A. Differences between asthma exacerbations and poor asthma control. Lancet 1999; 353(9150): 364–9Google Scholar
  43. 43.
    Reddel H, Jenkins C, Woolcock A. Diurnal variability—time to change asthma guidelines? BMJ 1999; 319(7201): 45–7PubMedCrossRefGoogle Scholar
  44. 44.
    Birring SS, Heartin E, Williams TJ, et al. Peak expiratory flow sequence in acute exacerbations of asthma. BMJ 2001; 322(7297): 1281PubMedCrossRefGoogle Scholar
  45. 45.
    Juniper EF, Cockcroft DW, Hargreave FE. Histamine and methacholine inhalation tests: a laboratory tidal breathing protocol. Lund: Astra Draco AB, 1994Google Scholar
  46. 46.
    Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161(1): 309–29PubMedGoogle Scholar
  47. 47.
    Barnes PJ. Effect of corticosteroids on airway hyperresponsiveness. Am Rev Respir Dis 1990; 141 (2 Pt 2): S70–6PubMedGoogle Scholar
  48. 48.
    Vathenen AS, Knox AJ, Wisniewski A, et al. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 1991; 143(6): 1317–21PubMedGoogle Scholar
  49. 49.
    Boulet LP, Turcotte H, Brochu A. Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission. Chest 1994; 105(4): 1024–31PubMedCrossRefGoogle Scholar
  50. 50.
    Leuppi JD, Salome CM, Jenkins CR, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163(2): 406–12PubMedGoogle Scholar
  51. 51.
    Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999; 159 (4 Pt 1): 1043–51PubMedGoogle Scholar
  52. 52.
    Green RH, Brightling CE, Woltmann GW, et al. Analysis of induced sputum in adults with asthma: identification of a subgroup with neutrophilic inhaled corticosteroid resistant disease. Thorax 2002; 57: 875–9PubMedCrossRefGoogle Scholar
  53. 53.
    Pizzichini E, Pizzichini MM, Efthimiadis A, et al. Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood. J Allergy Clin Immunol 1997; 99(4): 539–44PubMedCrossRefGoogle Scholar
  54. 54.
    Baba K, Hattori T, Koishikawa I, et al. Serum eosinophil cationic protein for predicting the prognosis of a step-down in inhaled corticosteroid therapy in adult chronic asthmatics. J Asthma 2000; 37(5): 399–408PubMedCrossRefGoogle Scholar
  55. 55.
    Baba K, Sakakibara A, Yagi T, et al. Long-term observations of the clinical course after step down of corticosteroid inhalation therapy in adult chronic asthmatics: correlation with serum levels of eosinophil cationic protein. Respirology 2002; 7(3): 255–66PubMedCrossRefGoogle Scholar
  56. 56.
    Prehn A, Seger RA, Torresani T, et al. Evaluation of a clinical algorithm involving serum eosinophil cationic protein for guiding the anti-inflammatory treatment of bronchial asthma in childhood. Pediatr Allergy Immunol 2000; 11(2): 87–94PubMedCrossRefGoogle Scholar
  57. 57.
    Bosse M, Chakir J, Rouabhia M, et al. Serum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. Am J Respir Crit Care Med 1999; 159(2): 596–602PubMedGoogle Scholar
  58. 58.
    Schedin U, Frostell C, Persson MG, et al. Contribution from upper and lower airways to exhaled endogenous nitric oxide in humans. Acta Anaesthesiol Scand 1995; 39(3): 327–32PubMedCrossRefGoogle Scholar
  59. 59.
    Kharitonov SA, Yates D, Robbins RA, et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994; 343(8890): 133–5PubMedCrossRefGoogle Scholar
  60. 60.
    Persson MG, Zetterstrom O, Agrenius V, et al. Single-breath nitric oxide measurements in asthmatic patients and smokers. Lancet 1994; 343(8890): 146–7PubMedCrossRefGoogle Scholar
  61. 61.
    Hamid Q, Springall DR, Riveros-Moreno V, et al. Induction of nitric oxide synthase in asthma. Lancet 1993; 342(8886-8887): 1510–3PubMedCrossRefGoogle Scholar
  62. 62.
    Saleh D, Ernst P, Lim S, et al. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. FASEB J 1998; 12(11): 929–37PubMedGoogle Scholar
  63. 63.
    Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 1996; 153(1): 454–7PubMedGoogle Scholar
  64. 64.
    Massaro AF, Gaston B, Kita D, et al. Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med 1995; 152(2): 800–3PubMedGoogle Scholar
  65. 65.
    Kharitonov SA, Yates DH, Chung KF, et al. Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. Eur Respir J 1996; 9(2): 196–201PubMedCrossRefGoogle Scholar
  66. 66.
    Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161(1): 64–72PubMedGoogle Scholar
  67. 67.
    Little SA, Chalmers GW, MacLeod KJ, et al. Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. Thorax 2000; 55(3): 232–4PubMedCrossRefGoogle Scholar
  68. 68.
    Smith AD, Cowan J, Brasset KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352(21): 2163–73PubMedCrossRefGoogle Scholar
  69. 69.
    Zacharasiewicz A, Wilson N, Lex C, et al. Clinical use of non-invasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med 2005; 171: 1077–82PubMedCrossRefGoogle Scholar
  70. 70.
    Zayasu K, Sekizawa K, Okinaga S, et al. Increased carbon monoxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 1997; 156 (4 Pt 1): 1140–3PubMedGoogle Scholar
  71. 71.
    Lim S, Groneberg D, Fischer A, et al. Expression of heme oxygenase isoenzymes 1 and 2 in normal and asthmatic airways: effect of inhaled corticosteroids. Am J Respir Crit Care Med 2000; 162(5): 1912–8PubMedGoogle Scholar
  72. 72.
    Olopade CO, Zakkar M, Swedler WI, et al. Exhaled pentane levels in acute asthma. Chest 1997; 111(4): 862–5PubMedCrossRefGoogle Scholar
  73. 73.
    Paredi P, Kharitonov SA, Barnes PJ. Faster rise of exhaled breath temperature in asthma: a novel marker of airway inflammation? Am J Respir Crit Care Med 2002; 165(2): 181–4PubMedGoogle Scholar
  74. 74.
    Kharitonov SA, Barnes PJ. Exhaled markers of inflammation. Curr Opin Allergy Clin Immunol 2001; 1(3): 217–24PubMedGoogle Scholar
  75. 75.
    Pavord ID, Pizzichini MM, Pizzichini E, et al. The use of induced sputum to investigate airway inflammation. Thorax 1997; 52(6): 498–501PubMedCrossRefGoogle Scholar
  76. 76.
    Fahy JV, Liu J, Wong H, et al. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993; 147(5): 1126–31PubMedGoogle Scholar
  77. 77.
    Gibson PG, Girgis-Gabardo A, Morris MM, et al. Cellular characteristics of sputum from patients with asthma and chronic bronchitis. Thorax 1989; 44(9): 693–9PubMedCrossRefGoogle Scholar
  78. 78.
    Pizzichini E, Pizzichini MM, Leigh R, et al. Safety of sputum induction. Eur Respir J Suppl 2002; 37: 9S–18SPubMedGoogle Scholar
  79. 79.
    Paggiaro PL, Chanez P, Holz O, et al. Sputum induction. Eur Respir J Suppl 2002; 37: 3S–8SPubMedGoogle Scholar
  80. 80.
    Djukanovic R, Sterk PJ, Fahy JV, et al. Standardised methodology of sputum induction and processing. Eur Respir J Suppl 2002; 37: 1S–2SPubMedCrossRefGoogle Scholar
  81. 81.
    Maestrelli P, Saetta M, Di Stefano A, et al. Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage. Am J Respir Crit Care Med 1995; 152 (6 Pt 1): 1926–31PubMedGoogle Scholar
  82. 82.
    Fahy JV, Wong H, Liu J, et al. Comparison of samples collected by sputum induction and bronchoscopy from asthmatic and healthy subjects. Am J Respir Crit Care Med 1995; 152(1): 53–8PubMedGoogle Scholar
  83. 83.
    Belda J, Leigh R, Parameswaran K, et al. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med 2000; 161 (2 Pt 1): 475–8PubMedGoogle Scholar
  84. 84.
    Claman DM, Boushey HA, Liu J, et al. Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects. J Allergy Clin Immunol 1994; 94(5): 861–9PubMedCrossRefGoogle Scholar
  85. 85.
    Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001; 119(5): 1329–36PubMedCrossRefGoogle Scholar
  86. 86.
    Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160(3): 1001–8PubMedGoogle Scholar
  87. 87.
    Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000; 356(9240): 1480–5PubMedCrossRefGoogle Scholar
  88. 88.
    Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998; 158 (5 Pt 1): 1511–7PubMedGoogle Scholar
  89. 89.
    Pizzichini MM, Pizzichini E, Parameswaran K, et al. Nonasthmatic chronic cough: no effect of treatment with an inhaled corticosteroid in patients without sputum eosinophilia. Can Respir J 1999; 6(4): 323–30PubMedGoogle Scholar
  90. 90.
    Godon P, Boulet LP, Malo JL, et al. Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids. Eur Respir J 2002; 20(6): 1364–9PubMedCrossRefGoogle Scholar
  91. 91.
    Pizzichini MM, Pizzichini E, Clelland L, et al. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med 1997; 155(5): 1501–8PubMedGoogle Scholar
  92. 92.
    Giannini D, Di Franco A, Cianchetti S, et al. Analysis of induced sputum before and after withdrawal of treatment with inhaled corticosteroids in asthmatic patients. Clin Exp Allergy 2000; 30(12): 1777–84PubMedCrossRefGoogle Scholar
  93. 93.
    Green RH, Brightling CE, McKenna S, et al. Reduced asthma exacerbations with a management strategy directed at normalising the sputum eosinophil count. Lancet 2002; 360: 1715–21PubMedCrossRefGoogle Scholar
  94. 94.
    Lane SJ, Lee TH. Mononuclear cells in corticosteroid-resistant asthma. Am J Respir Crit Care Med 1996; 154 (2 Pt 2): S49–51PubMedGoogle Scholar
  95. 95.
    Sher ER, Leung DY, Surs W, et al. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994; 93(1): 33–9PubMedCrossRefGoogle Scholar
  96. 96.
    Chakir J, Hamid Q, Bosse M, et al. Bronchial inflammation in corticosteroid-sensitive and corticosteroid-resistant asthma at baseline and on oral corticosteroid treatment. Clin Exp Allergy 2002; 32(4): 578-82PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Christopher E. Brightling
    • 1
  • Ruth H. Green
    • 1
  • Ian D. Pavord
    • 1
  1. 1.Institute for Lung HealthUniversity of Leicester and University Hospitals of LeicesterLeicesterUK

Personalised recommendations